Wannabe,

Conclusion: The results of this 6 year open labeled study comparing the immunomodulating effects of these four therapies in R-R MS patients has shown no statistically significant difference in terms of annual exacerbation rate, execerbation frequency and MRI disease activity.[/QUOTE]

I guess this means that the company who has the best marketing/sales group of the "big four" pharmas in MS drugs is going to get the largest market share of the business!!

Harry